Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort
Real‐world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short‐term clinical outcomes of lecanemab in practice in Japan.